Cure SMA Drug Discovery Initiative

Cure SMA's Drug Discovery Initiative funds preclinical work that turns SMA biology into new drug candidates. It sits alongside the organization's basic research program and serves as Cure SMA's translational route for moving promising concepts toward clinical testing. The initiative has backed 12 drug development projects totaling more than $20 million, with a typical project level around $300,000. Awards are issued irregularly when the Translational Advisory Council identifies a gap, so the program is currently between cycles rather than on a fixed annual calendar. Eligibility is global and limited to SMA drug discovery. The program has already contributed to FDA approvals including Spinraza, Zolgensma, Evrysdi, Itvisma, and High-Dose Spinraza. It is best suited to teams with a credible therapeutic concept, a clear development path, and enough scientific traction to benefit from seed funding while the work is still preclinical. Projects tend to fit best when the team can keep moving even before a full clinical package is ready.

No upcoming rounds verified. Cadence: One-off.